A LinkedIn post from Tubulis indicates the company plans to participate in the 5th Novel Conjugate Summit 2026 in Boston from March 17–19. The post notes that Tubulis executives will engage in discussions on the future of targeted conjugate therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Vice President of Chemistry and Early Discovery Marc-André Kasper is scheduled to co-lead a workshop with AstraZeneca’s Sujiet Puthenveetil on next-generation linker and conjugation strategies. The post also mentions a presentation on how Tubulis’ conjugation platforms and linker technologies may enable stable, high-performing degrader-antibody conjugates.
The content suggests Tubulis continues to position itself as a specialist in advanced antibody-drug and related conjugate technologies, an area of growing interest in oncology and targeted therapies. Visibility at a sector-focused summit and collaboration with a major pharma partner on workshop content could support Tubulis’ credibility, potentially aiding future partnerships, licensing deals, or fundraising.
For investors, the emphasis on next-generation linker and conjugation strategies underscores the company’s effort to differentiate its platform on stability and performance, which are key technical risk factors in this field. If the technologies described in the post translate into superior clinical or preclinical data, Tubulis could strengthen its competitive position within the antibody-drug conjugate and degrader-conjugate ecosystem.